- All sections
- C - Chemistrymetallurgy
- C07K - Peptides
- C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
Patent holdings for IPC class C07K 16/30
Total number of patents in this class: 11671
10-year publication summary
868
|
1033
|
1078
|
1093
|
1124
|
1054
|
1076
|
1033
|
954
|
532
|
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Immatics Biotechnologies GmbH | 1157 |
412 |
Genentech, Inc. | 3980 |
198 |
Regeneron Pharmaceuticals, Inc. | 4253 |
150 |
The Regents of the University of California | 19929 |
149 |
Hoffmann-La Roche Inc. | 3422 |
145 |
F. Hoffmann-La Roche AG | 7921 |
144 |
Memorial Sloan-Kettering Cancer Center | 1930 |
132 |
The United States of America, as represented by the Secretary, Department of Health and Human Services | 2853 |
130 |
The Trustees of the University of Pennsylvania | 4323 |
116 |
Amgen Inc. | 4044 |
111 |
Chugai Seiyaku Kabushiki Kaisha | 1357 |
110 |
Janssen Biotech, Inc. | 1548 |
105 |
Amgen Research (Munich) GmbH | 253 |
93 |
Novartis AG | 10850 |
91 |
Immunomedics, Inc. | 259 |
89 |
SeaGen Inc | 589 |
87 |
The Board of Trustees of the Leland Stanford Junior University | 6416 |
86 |
Board of Regents, The University of Texas System | 5803 |
84 |
Dana-Farber Cancer Institute, Inc. | 2564 |
82 |
Daiichi Sankyo Company, Limited | 1874 |
79 |
Other owners | 9078 |